Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04093622 · ClinicalTrials.gov registry record
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
A clinical trial, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- 2
- Enrollment target
NCT04093622: Clinical Trial study, sponsored by Fate Therapeutics.
NCT04093622 is a clinical trial that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04093622 was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years starting from the last administration of Fate Therapeutics genetically modified NK cell product, subjects will be assessed for long-term safety and survival through questionnaires and blood tests.
Primary Outcome
OS defined as the interval between the date of first Fate Therapeutics genetically modified NK cell product infusion and date of death due to any cause.
Interventions
- GENETIC Genetically engineered NK cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-10-04 |
| Est. Completion | 2020-04-09 |
Why NCT04093622 stopped before completion
NCT04093622 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Genetically engineered NK cells is the first listed.
NCT04093622 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04093622 about?
NCT04093622 is a clinical study titled "Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy". The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. ...
What is the current status of trial NCT04093622?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-10-04. Estimated completion is 2020-04-09.
What interventions are being tested in trial NCT04093622?
The interventions under investigation include: Genetically engineered NK cells (GENETIC).
Who is sponsoring clinical trial NCT04093622?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI